Anti-L-selectin monoclonal antibodies - PDL BioPharma
Alternative Names: Anti-L-selectin monoclonal antibody DREG 200 - PDL BioPharma; Anti-L-selectin monoclonal antibody DREG 55; Aselizumab; BNP 001; DREG 200 - PDL BioPharma; DREG 55; hDREG-200 - PDL BioPharma; hDREG-55; Hu DREG 55; SMART anti-L-selectin antibodiesLatest Information Update: 24 May 2006
At a glance
- Originator PDL BioPharma
- Class Monoclonal antibodies
- Mechanism of Action L-selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Shock
- Discontinued Adult respiratory distress syndrome; Crohn's disease; Psoriasis; Reperfusion injury
Most Recent Events
- 22 May 2006 No development reported - Preclinical for Shock in USA (unspecified route)
- 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
- 18 Aug 2005 Data presented at the 66th Annual Meeting of the Society for Investigative Dermatology (SID-2005) have been added to the Skin disorders therapeutic trials section